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Purpose of review 
We assess studies on vector systems for delivery of transgenes to the cornea that 
have been published over the last year, and summarise new work on the 
identification of specific transgenes for corneal diseases. 
Recent findings 
Adeno-associated viral vectors (AAV) are increasingly being successfully applied to 
the cornea, although transgene expression requires corneal epithelial debridement, 
or intrastromal injection of the vector. Gene delivery platforms based on 
nanoparticles of chitosan or gold also show promise. Over-expression of vasoinhibin-
1 or decorin, or siRNA-mediated blockade of the cannabinoid receptor CB1, can all 
reduce corneal neovascularization. Over-expression of decorin or matrix 
metalloproteinase 14 can reduce corneal fibrosis and haze, while over-expression of 
c-Met accelerates epithelial wound healing. Induction of corneal endothelial cell 
replication by over-expression of E2F2, p16 or p21 can maintain or even increase 
corneal endothelial cell density in eye bank corneas. Over-expression of the anti-
apoptotic transgenes Bcl-xL or p35 significantly enhances corneal endothelial cell 
survival and reduces apoptosis in stored human corneas.  
Summary 
Despite a wealth of information on methods for the delivery of nucleic acids to the 
human cornea, and ever-increasing information transgenes with substantial 
therapeutic potential, gene therapy for corneal disorders has yet to reach the clinic. 
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Key Points 
• Adeno-associated viral vectors (AAV), and delivery platforms based on 
nanoparticles, are being successfully applied to the cornea. 
• Corneal neovascularization can be reduced by over-expression of inhibin-1 or 
decorin. Blockade of the CB1 cannabinoid receptor shows particular promise 
because of its specificity for actively-proliferating endothelial cells. 
• Use of gene therapy to prevent stromal scarring and haze after refractive 
surgery, or to accelerate corneal epithelial healing, now appears within reach. 
• Gene transfer approaches designed to increase or maintain corneal 
endothelial cell density in human donor corneas retrieved for corneal 
transplantation include the reduction of endothelial cell apoptosis, or the 
induction of endothelial cell replication by modulation of the cell cycle. 
• Despite ever-increasing availability of suitable viral and non-viral vector 
delivery systems, and a plethora of suitable transgenes, gene therapy for the 
human cornea has yet to reach clinical practice. 
 
Archived at Flinders University: dspace.flinders.edu.au
 4 
Introduction 
Gene therapy for the correction of diseases affecting the cornea has been mooted for 
twenty years, and has been applied in a wide variety of experimental models. In this 
review, we assess recent work on vector systems for delivery of transgenes to the 
cornea, and also examine the outcomes of delivery of specific transgenes for specific 
conditions. Virtually all the reported work on corneal gene therapy over the past year 
has been in animal models, or on human cells in vitro or on human corneas ex vivo. 
 
Viral vectors for use in the cornea 
Viral gene therapy vectors are incomparably efficient, producing rapid, high-level 
expression of the requisite transgene. The major classes of viral vectors used 
hitherto to transfect the cornea successfully have been adenoviral vectors and 
lentiviral vectors. However, over the past year, the use of adeno-associated (AAV) 
viral vectors has been further explored [1-3]. Serotypes AAV6, AAV8 and AAV9 were 
shown to transduce both murine and human corneas following removal of the 
epithelium, with AAV9 being the most efficient [1]. AAV5 was shown by the same 
investigators to be able to transduce equine corneal fibroblasts in vitro [2] and the 
rabbit cornea [3]. In corneas, expression of the transgene was maximal after about 7-
14 days. An alternative strategy was delivery by injection into the corneal stroma, 
which also yielded good expression for serotype AAV2 in murine corneas [4]. 
However, these approaches may be limited in their clinical utility, since extensive 
corneal epithelial debridement and stromal injection both carry some risks of 
morbidity. However, the application of AAV vectors to the cornea is interesting in the 
light of the successful use of AAV2 in clinical trials for Leber's congenital amaurosis 
[e.g. 5], because many of the issues in producing clinical-grade vector stocks and in 
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handling the ethical and regulatory frameworks have already been overcome. 
 
Further work has also been reported with lentiviral vectors. An HIV-1-based lentiviral 
vector carrying the transgene ovine interleukin 10 was used to transfect ovine 
corneal endothelium ex vivo prior to orthotopic corneal transplantation in outbred 
sheep [6]. Corneal allograft survival, the endpoint of interest, was prolonged to a 
modest but statistically significant extent, compared with the control group. In another 
study, a commercially-available lentiviral vector was shown to transduce rabbit 
primary epithelial cells cultured ex vivo. After a short delay in expression, a reporter 
gene was stably expressed over time in a dose-dependence fashion, and was 
transferred not only to mature corneal epithelial cells, but also to putative epithelial 
stem cells [7], paving the way for future gene transfer approaches to improve 
outcomes for limbal stem cell dysfunction. 
 
Relatively little new work has been performed with adenoviral (AV) vectors, but of 
note was the successful delivery of the c-Met gene to human corneal epithelium in 
vitro, using a combination of long transduction time (48 hours) and sildenafil (Viagra) 
at 75 µg/ml as a transduction enhancer [8]. In another study, subconjunctival injection 
of an AV vector expressing human vasohibin-1 resulted in expression in the central 
corneal stroma in an in vivo mouse model [9]. It is clear that despite the many 
problems associated with adenoviral gene therapy vectors, they are still favoured by 
a number of investigators for use in the cornea. 
 
Gene delivery platforms involving nanotechnology 
A number of groups are investigating the use of nanoparticles and nanomaterials as 
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platforms for drug, cell and nucleotide transfer to the eye. One such interesting and 
well-developed system is based on the hydrophilic, cationic polysaccharide chitosan, 
which has been adapted for the delivery of both hydrophilic and lipophilic drugs such 
as indomethacin and cyclosporin A, and (of more importance in the current context) 
polynucleotides, to the ocular surface [10]. Chitosan therefore has some potential for 
gene therapy directed to the cornea and conjunctiva. Commercially-available 
ultrapure (bacterial endotoxin-low) chitosan oligomers complexed with cDNA 
encoding a reporter gene have been shown to transfect rat keratocytes following 
intrastromal injection, but the formulation of chitosan-containing nanoparticles was 
not more effective than was the direct injection of naked DNA [11]. Topical delivery of 
the chitosan nanoparticles to the eye, which would have been of great interest, was 
not examined in this study. 
 
Another platform for gene delivery is based on gold nanoparticles. Sharma et al [12] 
have explored the potential of polyethylenimine-conjugated gold nanoparticles 
(GNPs) for gene transfer to the corneal stroma. Successful transduction of human 
corneal fibroblast cultures in vitro, and rabbit corneas in vivo, was observed. Of 
particular interest was the relatively slow release of the nucleic acid cargo and the 
slow clearance from the target tissue. However, in vivo clearance rates may be 
affected by the degree of neovascularization. The GNPs exhibited good 
biocompatibility, although toxicity was dependent on the nitrogen to phosphorus ratio 
used to prepare the particles. Despite gold particles being demonstrable in the 
cornea, there was no apparent visual disturbance. The fact that gold nanoparticles 
were found both within corneal cell nuclei and the extracellular matrix suggests that 
such particles may also be suitable for slow-release drug delivery (rather than gene 
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delivery) to the cornea. 
 
Gene therapy for corneal dystrophies  
Whilst mutations in the genes causing some of the corneal dystrophies are now well 
characterised, little practical progress has been made in gene therapy in humans 
[13]. However for Meesmann epithelial corneal dystrophy, which is caused by a 
dominant-negative mutation in either keratin K3 or K12 in the anterior corneal stroma, 
in vitro data on cultured cells suggested that an siRNA against a mutant allele of the 
keratin gene might provide some therapeutic benefit [14].  
 
Approaches to reduce corneal neovascularization 
The significant role of vascular endothelial growth factor-A (VEGF) in corneal 
neovascularization has long been recognised, and interference with the VEGF 
signalling pathway has been approached by several groups in different ways. 
Subconjunctival injection of an AV vector encoding human vasohibin-1 significantly 
reduced corneal neovascularization in mouse corneas subjected to alkaline burns, 
and the effect appeared to be related to down-regulation of VEGF-R2-expression [9]. 
Only the effect on inflammation-driven neovascularization was examined, and 
potential effects on other types of ocular neovascularization would be of interest. 
 
Blockade of the cannabinoid receptors CB1 and CB2 has been previously reported to 
inhibit VEGF signalling, and CB1-specific pharmacological blockade or siRNA-
mediated knockdown of CB1 has been shown to inhibit basic fibroblast growth factor 
(bFGF)-driven vascular endothelial proliferation, migration and tube formation [15]. A 
strong synergy between VEGF and bFGF in the induction of neovascularization is 
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well recognised. These effects were replicated in an in vivo model of rabbit corneal 
neovascularization (an example of an inflammatory process), and also in a mouse 
model of oxygen-induced retinopathy, indicating the importance of this pathway for 
neovascularization independent of the initiating factor. Importantly, only actively 
proliferating vascular endothelial cells were affected, suggesting that blockade of 
CB1 might be an interesting target for new anti-angiogenic strategies, with little risk of 
a non-specific toxic effect in the pre-existing mature vasculature.  
 
In an in vivo rabbit model of VEGF-induced corneal neovascularization, AAV-
mediated expression of decorin, a small leucine-rich proteoglycan, also resulted in 
significant inhibition of neovascularization [16]. A marked decrease in VEGF 
expression at the mRNA level in corneas treated with decorin suggests that the anti-
angiogenic effects observed were at least in part due to attenuation of VEGF 
expression by inflammatory cells recruited to the tissue. However, decorin, which is 
expressed by normal cornea, also interacts with growth factors including transforming 
growth factor-beta (TGFβ) to regulate collagen fibrillogenesis and extracellular matrix  
deposition, both of which are crucial in corneal wound healing. Decorin is thus an 
attractive target for gene therapy approaches to reducing corneal scarring and haze 
[17]. 
 
Gene therapy for corneal scarring 
Expression of TGFβ in the healthy cornea is restricted to the corneal epithelium, but 
this growth factor is secreted into the stroma during wound healing where it 
contributes to myofibroblast formation, haze and scarring [18]. AAV-mediated over-
expression of decorin by human corneal fibroblast cultures did not alter cell 
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morphology or viability, but prevented TGFβ-driven transformation of keratocytes and 
corneal fibroblasts to myofibroblasts [19]. Subsequent in vivo studies in a rabbit 
model of laser-induced corneal fibrosis confirmed the inhibition of myofibroblast 
formation and reduction of haze, and demonstrated no immunogenic or toxic effects 
[20]. 
 
Other approaches have included over-expression of matrix metalloproteinase 14 by 
corneal stroma in vivo in a murine model of corneal scarring. In this model, fibrotic 
repair also occurs via differentiation of keratocytes into myofibroblasts, which was 
significantly inhibited, along with collagen type III deposition [21]. However, some 
severe toxic effects were evident at higher doses when virus was injected into the 
corneal stroma. 
 
One of the difficulties with these and similar models is the need to either debride the 
corneal epithelium prior to gene delivery, or to inject the viral vector directly into the 
corneal stroma. For improvement of wound healing in human corneas of diabetes-
affected donors, who suffer from down-regulation of migratory growth factors such as 
hepatocyte growth factor (HGF), over-expression of the HGF receptor c-Met led to 
normalisation of HGF signalling and accelerated epithelial wound healing in vitro [8]. 
This approach was especially attractive because an improved delivery technique did 
not involve corneal epithelial ablation to facilitate gene delivery. Adenoviral–mediated 
gene expression is only short term, and diabetic patients may benefit most from this 
type of therapy in the event of an acute injury. In any case, short-term gene 
expression is probably preferable, given that long-term expression of the proto-
oncogene c-Met might yield unexpected side-effects, including malignancy.  
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Approaches to protection of corneal endothelium and epithelium 
Gene transfer approaches designed to increase or maintain corneal endothelial cell 
density in human donor corneas retrieved for corneal transplantation have recently 
been elegantly reviewed by Kampik, Ali and Larkin [22]. The options include the 
reduction of endothelial cell apoptosis, or the induction of endothelial cell replication 
by modulation of the cell cycle. Anti-apoptotic transgenes under investigation include 
Bcl-xL and p35 [23,24]. Transgenes designed to induce endothelial cell replication 
include E2F2, encoding a transcription factor that induces cell cycle progression, and 
p16 and p21, which encode cyclin-dependent kinase negative regulators of the cell 
cycle [22]. Over-expression of either mammalian Bcl-xL or baculoviral p35 in human 
Eye Bank corneas, following transduction with a lentiviral vector, significantly 




A number of reviews of gene therapy for the cornea have been published over the 
past year, each with a somewhat different emphasis [13,22,25].  
 
Conclusion 
Where are we with respect to translating gene therapy into benefits for individuals 
with cornea disease? Sadly, not very far. Despite a wealth of information on methods 
for the delivery of nucleic acids to the cornea, including the human cornea, and 
increasing information on the mutations that are disease-causative in humans, 
especially in corneal dystrophies, clinical trial data on gene therapy for corneal 
disorders have yet to be published. 
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